Top Markets
Coin of the day
Eli Lilly Eli Lilly

Eli Lilly

LLY
주식 순위 #15
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals... Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
주가
$910.55
시가총액
$860.30B
변동 (1일)
0.44%
변동 (1년)
5.28%
국가
US
거래 Eli Lilly (LLY)

카테고리

Eli Lilly (LLY)의 영업이익률
March 2026 기준 영업이익률 TTM: 45.56%
Eli Lilly의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 45.56%입니다. 2024년 말 기준 영업이익률은 38.86%였습니다.
Eli Lilly의 영업이익률 기록 (2000 ~ 2026)
매년 말 영업이익률
연도 영업이익률 변화
2026 (TTM) 45.56% 0.00%
2025 45.56% 17.24%
2024 38.86% 22.94%
2023 31.61% 4.25%
2022 30.32% 8.25%
2021 28.01% -4.66%
2020 29.38% 9.30%
2019 26.88% -4.14%
2018 28.04% 31.77%
2017 21.28% 16.67%
2016 18.24% 1.33%
2015 18.00% 6.07%
2014 16.97% -29.29%
2013 24.00% 8.16%
2012 22.19% -14.69%
2011 26.01% -11.38%
2010 29.35% 0.62%
2009 29.17% 7.52%
2008 27.13% 5.24%
2007 25.78% -1.94%
2006 26.29% 5.54%
2005 24.91% -5.64%
2004 26.40% -5.14%
2003 27.83% -7.36%
2002 30.04% -7.03%
2001 32.31% -1.40%
2000 32.77% 0.00%
유사 기업 또는 경쟁사의 영업이익률
회사 영업이익률 영업이익률 차이 국가
23.28% -99.49%
GB
27.17% -99.40%
US
26.72% -99.41%
US
31.24% -99.31%
CH
41.19% -99.10%
US
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.